Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
The Course of COVID-19 Infection in Patients After Pancreas and Kidney Transplantation: A Single-Center Observation

Marta Matejak-Górska, Hanna Górska, Michał Zielonka, and Marek Durlik

aDepartment of General Surgery and Transplantology, Central Clinical Hospital of the Ministry of the Interior and Administration in Warsaw, Warsaw, Poland; bCenter of Postgraduate Medical Education, Department of General Surgery and Transplantology, Warsaw, Poland; and cUniversity of Warmia and Mazury in Olsztyn, Olsztyn, Poland

ABSTRACT

Solid graft recipients are at an increased risk of serious complications and death. Out of 130 outpatient recipients of pancreas grafts at our Clinic, 20 patients (15.73%) had a confirmed severe acute respiratory syndrome coronavirus 2 infection (SARS-CoV-2). Each patient had a different course of the disease, and the forms of infection varied from mild to severe and lethal. According to recommendations, after confirmation of the infection, mycophenolate mofetil was withdrawn and the immunosuppression was based on steroids and a calcineurin inhibitor. In this study, we performed an analysis of the course of COVID-19 infection in patients after pancreatic transplantation. Twenty pancreas recipients were confirmed to have COVID-19 infections; 4 of whom required hospitalization owing to severe complications. Patients reported weakness, excessive intensity of fatigue, shortness of breath with exertion, cough, and periodically increased temperature. Weakness and fatigue persisted in these patients for about 6 weeks. In 2 patients there was a need for oxygen supplementation and empirical antibiotic. Mortality was 5%, and there was 1 graftectomy. Deterioration of either kidney or pancreas graft were not observed in any other patients. The course of SARS-CoV-2 infection in solid graft recipients is similar to that of the rest of the population. Because of immunosuppression, recipients were accustomed to avoiding crowds and complying with obligations to wear masks.

THE number of individuals confirmed to be infected with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus has exceeded 398.6 million worldwide. More than 5.7 million patients have died of COVID-19 since the start of the pandemic. The most affected regions in the world are Europe (more than 136.9 million cases), Asia (more than 104.9 million cases), and North America (more than 91.8 million cases). Europe is the region where COVID-19 has the highest death toll. Of all those who died of COVID-19 worldwide, 28.5% died in Europe. Fatalities in Asia are 22.7% percent of all deaths related to COVID-19 [1].

People on dialysis become infected with COVID-19 8 times more often than the general population. According to the report of the National Nephrology Consultant in September 2021 [2], 1 person in 2500 hemodialysis patients developed COVID-19, whereas the incidence in the entire population of our country was then 1 person in 50,000. On the other hand, the number of dialysis patients in Poland fluctuated during the pandemic between 20,000 and 22,000. At the beginning of the pandemic, the incidence was 10 times higher, but almost 90% of dialyzed patients were vaccinated against COVID-19, hence a significant decrease in the incidence in this group of patients [3]. Due to the reduced immunity in dialysis patients and patients after organ transplantation, in Poland and other countries, it is recommended to perform booster vaccinations in this group of patients [4,5].

The recommendations of the Polish Transplant Society at the beginning of the SARS-CoV-2 pandemic resulted in a significant reduction in the number of organ transplants in Poland. The number of hospitals in which transplantations took place decreased, as
did the number of organ donors. According to Poltransplant data [6], 4 pancreatic transplants were performed in 2020 and 20 were performed in 2021. Our center was transformed into a COVID-19 hospital that did not perform any pancreatic transplantation from March 2020 to May 2021; in previous years, we performed more than 20 such procedures annually.

The aim of this study was to describe the experience of our clinic with pancreas graft recipients with confirmed COVID-19 infection and to evaluate the effect of the infection on graft function.

METHODS
A retrospective analysis of pancreas recipients with confirmed SARS-CoV-2 infection was performed. We analyzed the time from transplant, age, sex, and data on symptoms of the infection.

We have previously described our surgical technique and comprehensive management [7–10]. We perform a longitudinal midline incision and anastomose pancreas arterial Y-graft and portal vein to the right iliac vessels of the donor. We create a double-layered handsewn side-to-side junction between duodenum and proximal jejunum. We transplant the kidney from the same median incision into retroperitoneal space behind the left iliac vessels. We use a 3-drug immunosuppression scheme with induction with polyclonal antibodies thymoglobulin—total dose of 1.5 mg/kg. According to recommendations, after confirmation of a COVID-19 infection, mycophenolate mofetil was withdrawn and the immunosuppression based on steroids and a calcineurin inhibitor. During the SARS-CoV-2 infection, we did not change anticoagulant treatment in a group of patients with mild symptoms. Three months post-transplantation, recipients were administered 75 mg of acetylsalicylic acid daily. In a group of patients with moderate or severe infection symptoms, low molecular weight heparin in a prophylactic dose was administered.

Our center transformed into a COVID-19 hospital in March 2020. To continue observing the recipients, outpatient care during the pandemic was under telemedicine services and on-demand in person. Controls and laboratory examinations took place in an ambulatory area created exclusively for patients on immunosuppression. The aim creating the ambulatory area was to limit possible contact with SARS-CoV-2 positive patients.

Since changes in restrictions, it was mandatory to perform a polymerase chain reaction (PCR) test for SARS-CoV-2 infection and a chest high resolution computed tomography (CT) in each solid graft donor. Also, recipients were obliged to have a PCR test and chest radiograph. Currently, after a series of vaccinations against COVID-19, the population of potential organ recipients is less vulnerable to infection, and we are slowly withdrawing from restrictions. In May 2021, at our clinic, the pancreas transplantation program was reactivated.

RESULTS
Out of 130 recipients in the outpatient observation, 20 recipients (15.3%) were diagnosed with SARS-CoV-2. Table 1 summarizes the clinical data of the recipients. There were 14 women and 6 men, and 17 patients (85%) underwent simultaneous pancreas and kidney transplantation (SPK) and 3 patients had only a pancreas transplantation. The mean time from the transplantation to COVID-19 infection was 3.88 years.

All infected patients were advised to discontinue mycophenolate for approximately 2 to 3 weeks. Three patients after COVID-19 infection had digestive tract disorders, including diarrhea, which resolved after conservative treatment.

Four patients from the observation developed COVID-19 infection after 2 doses of mRNA vaccination, and 11 patients were vaccinated after recovery from the infection. During infection, patients reported weakness, excessive fatigue, shortness of breath with exertion, cough, and periodically increased temperature. Weakness and fatigue persisted in these patients for about 6 weeks.

Among the patients, 20% presented moderate symptoms of the infection. In a single patient, the course of SARS-CoV-2 was serious. The overall mortality was 5%, and there was 1 graftectomy. No deterioration of either the kidney or the pancreas graft in any other patients was observed. One patient vaccinated before their SARS-CoV-2 infection required hospitalization owing to severe diarrhea and need of intravascular fluid administration. In 2 patients there was a need for oxygen supplementation and empirical antibiotic. The 3 other hospitalized patients are described below.

Patient 6: Aged 51 Years
The patient underwent SPK transplantation on September 28, 2017, and afterwards qualified for our study owing to insulin-dependent diabetes, chronic renal disease, and dialysis for 18 months before the transplant. Table 2 summarizes the most important data regarding transplantation and treatment.

In March 2021, the patient was diagnosed with COVID-19. The initial symptoms included weakness, fatigue, cough, headache, and muscle pain. No shortness of breath, decrease in saturation, or fever were observed. Conservative treatment was carried out in home isolation conditions. The drug modification included the withdrawal of mycophenolate mofetil. Maintaining the regimen of the rest of the drugs, steroids, tacrolimus, and acetylsalicylic acid was prescribed.

After 3 weeks, the PCR test was still positive. Because of increasing dyspnea, the patient was referred to an infectious hospital and hospitalized for 7 days. The thoracic CT revealed bilateral scattered irregular areas of the frosted glass type, with a predominance of peripheral segments, locally with visible densities and thickening of interlobular septa (a symptom of paving stones), moderate lesions affecting 25% to 50% of the lungs (Fig 1). No deterioration of kidney or pancreas graft function was observed. Table 3 presents the results at admission to the hospital.

The patient was treated with low molecular weight heparin in a prophylactic dose, as well as empirically administered ceftriaxone and amoxicillin with a beta-lactamase inhibitor. After improvement of her general condition, she was discharged from the clinic and sent home.

In May, June, and September 2021, the patient was vaccinated with the mRNA (Moderna) vaccine and obtained the level of IgG > 2080 BU/mL in the tests.

Currently, both grafts have sufficient function (creatinine 1.36 mg/dL, eGfr > 60 mL/min/1.73 m2). The patient is independent from insulin (HbA1c -5.7%). No further episodes of fatigue or shortness of breath were reported.
Table 1. Clinical Data of Pancreas Recipients After SARS-CoV-2 Infection

|   | Sex     | Type of Tx | Time (y) From Tx to COVID-19 | Age | Date of Infection | mRNA Vaccine I Dose Date | mRNA Vaccine II Dose Date | mRNA Vaccine III Dose Date | Hospitalization Due to SARS-CoV-2 Infection | Symptoms | Pancreas Graft Function After SARS-CoV-2 Infection |
|---|---------|------------|------------------------------|-----|-------------------|--------------------------|--------------------------|--------------------------|------------------------------------------|----------|--------------------------------------------------|
| 1 | Woman   | SPK        | 7                            | 50  | 12.20             | 06.21                    | 07.21                    | -                        | No                                       | Mild     | Good                                             |
| 2 | Woman   | SPK        | 9                            | 33  | 01.21             | 03.21                    | 05.21                    | -                        | No                                       | Mild     | Good                                             |
| 3 | Woman   | PTA        | 5                            | 34  | 11.20             | 03.21                    | 05.21                    | -                        | No                                       | Mild     | Good                                             |
| 4 | Man     | SPK        | 8                            | 55  | 10.20             | 08.21                    | 09.21                    | -                        | No                                       | Mild     | Good                                             |
| 5 | Woman   | SPK        | 6                            | 26  | 12.20             | 03.21                    | 05.21                    | 10.21                    | No                                       | Mild     | Good                                             |
| 6 | Man     | SPK        | 3                            | 51  | 03.21             | 05.21                    | 06.21                    | 09.21                    | Yes                                      | Moderate | Good                                             |
| 7 | Woman   | SPK        | 5                            | 34  | 12.20             | 03.21                    | 04.21                    | 11.21                    | No                                       | Mild     | Good                                             |
| 8 | Woman   | SPK        | 3                            | 45  | 11.20             | 03.21                    | 04.21                    | 12.21                    | No                                       | Mild     | Good                                             |
| 9 | Woman   | PTA        | 2                            | 36  | 12.21             | 03.21                    | 05.21                    | -                        | No                                       | Moderate | Good                                             |
|10 | Woman   | SPK        | 2                            | 37  | 02.20             | -                        | -                        | -                        | No                                       | Mild     | Good                                             |
|11 | Man     | SPK        | 4                            | 41  | 12.21             | 03.21                    | 04.21                    | 09.21                    | No                                       | Mild     | Good                                             |
|12 | Man     | SPK        | 2                            | 29  | 12.21             | 03.21                    | 05.21                    | -                        | No                                       | Mild     | Good                                             |
|13 | Woman   | SPK        | 1                            | 37  | 05.21             | 03.21                    | 06.21                    | 10.21                    | No                                       | Mild     | Good                                             |
|14 | Man     | SPK        | 0.5                          | 46  | 11.20             | 03.21                    | 04.21                    | -                        | No                                       | Mild     | Good                                             |
|15 | Woman   | SPK        | 2                            | 37  | 11.20             | 03.21                    | 05.21                    | 09.21                    | No                                       | Mild     | Good                                             |
|16 | Man     | SPK        | 0.5                          | 40  | 12.21             | 03.21                    | 04.21                    | 09.21                    | No                                       | Mild     | Good                                             |
|17 | Woman   | PTA        | 6                            | 41  | 04.21             | -                        | -                        | -                        | Yes                                      | Moderate | Graft loss (graftectomy due to venous thrombosis) |
|18 | Woman   | SPK        | 7                            | 48  | 01.20             | -                        | -                        | -                        | Yes                                      | Severe   | Death                                           |
|19 | Woman   | SPK        | 9                            | 42  | 01.22             | -                        | -                        | -                        | Yes                                      | Moderate | Good                                             |
|20 | Woman   | SPK        | 5                            | 48  | 04.21             | -                        | -                        | -                        | No                                       | Mild     | Good                                             |

PTA, pancreas transplantation alone; SPK, simultaneous pancreas and kidney transplantation; Tx, transplantation.
Case 17: aged 41 years

The patient underwent a pancreas transplant on January 30, 2015, and qualified for our study owing to insulin-dependent diabetes without renal complications. Table 4 shows transplantation details.

In April 2021, the patient tested positive for SARS-CoV-2 was detected. Initially, the patient manifested only mild symptoms. After 2 weeks, she was hospitalized because of severe muscle pain, headaches, and dry cough. The patient required oxygen supplementation. Thoracic CT showed peripheral inflammatory lesions of matt glass and paving stones, taking up about 8% of the lungs (Fig 2). During first days of hospitalization, there was no observable graft function deterioration (creatinine 1.68 mg/dL, eGFR 46 mL/min, c-peptide 3.13 ng/mL, HbA1 -5.5%), but only leukopenia 2.38 1000/μL was found. The conservative treatment was modified according to our standard (MMF withdrawal and low molecular weight heparin in prophylactic dose). After 2 weeks, she was discharged from the hospital with a recommendation to reduce steroid therapy within 2 weeks of discharge. After 4 months, the patient reported fatigue, abdominal pain, and hyperglycemia >500 mg/dL. In an abdominal CT scan, the transplanted pancreas was enlarged, heterogeneous, with edema, arterial vascularization of the graft from the right iliac artery only in the initial segment, and venous outflow only slightly visible in the proximal part (Fig. 3 and 4). Conservative treatment consisted of insulin therapy, therapeutic dose of heparin, and empirical antibiotic therapy. Endoscopic examination showed mucosal necrosis of the graft’s duodenum, mucosal surface without visible vessels. Patients was qualified for graftectomy. In the histopathological examination of the specimen of the transplanted pancreas, there

### Table 2. Case 6: History of Transplantation for Man Aged 51 Years

| Donor Deceased | Warm ischemia time | Cold ischemia time | Induction | Immunosuppression | Transplant complications | Surgical site infection |
|----------------|--------------------|--------------------|-----------|-------------------|--------------------------|------------------------|
| Deceased       | 30 min             | 380 min            | Polyclonal antibodies at a dose of 1.5 mg/kg | Steroids, tacrolimus, mycophenolate mofetil | Recuperation due to intra-abdominal abscesses | Wound |

### Table 3. Case 6: Laboratory Results on Discharge for Man Aged 51 Years

| Creatinine | 1.49 mg/dL |
|------------|------------|
| Estimated glomerular filtration rate | 50.1 mL/min/1.73 m² |
| Urea | 47 mg/dL, |
| Anti-SARS antibodies -CoV-2 IgG | positive result (116AU/mL) |
| Anti-SARS-CoV -2 antibodies-IgM | positive result (10.10 INDEX) |
| C-reactive protein | 21.8 mg |
| D-dimers | 1.61 μg/mL (r: 0-0.5). |

### Table 4. Case 17: History of Transplantation for 39-Year-Old Woman

| Donor Deceased | Warm ischemia time | Cold ischemia time | Induction | Immunosuppression | Transplant complications | Surgical site infection |
|----------------|--------------------|--------------------|-----------|-------------------|--------------------------|------------------------|
| Deceased       | 25 min             | 300 min            | Polyclonal antibodies at a dose of 1.5 mg/kg | Steroids, tacrolimus, mycophenolate mofetil | None | None |

**Fig 1.** Case 6. Chest computed tomography. Changes in the course of COVID-19. The thoracic computed tomography revealed a bilateral scattered irregular areas of the frosted glass type, with a predominance of peripheral segments, locally with visible densities and thickening of interlobular septa (symptom of paving stones), moderate lesions affecting 25% to 50% of the lungs.

**Fig 2.** Case 17. Chest computed tomography. Changes in the course of COVID-19. The thoracic computed tomography revealed peripheral inflammatory lesions of matt glass and paving stones, taking up about 8% of the lungs.
was observable atrophy and fibrosis of the graft, changes related to chronic rejection, vascular thrombosis, and hemorrhagic necrosis. After the graft was removed, the patient’s condition improved and the patient was discharged from the hospital and sent home. On discharge, the level of IgG was 791.0 BAU/mL, IgM 51.8 (index).

Case 18: Aged 48 Years

The patient underwent an SPK transplantation on December 29, 2017, and afterward qualified for our study owing to insulin-dependent diabetes, chronic renal disease, and dialysis for 32 months (peritoneal dialysis). Table 5 shows transplantation details.

In December 2020, the patient tested positive for SARS-CoV-2. The patient required referral to the local infectious hospital owing to fever and severe diarrhea. Two weeks later, the general condition worsened, and she was referred to our clinic, the third-level hospital for COVID-19 treatment. The patient required mask with a reservoir with oxygen flow 15l per minute. In a high-resolution CT of the chest, extensive consolidation and frosted glass changes, covering 75% to 80% of the lung volume, was found (Fig 5).

*Clostridium difficile* was detected in stool and vancomycin was administrated orally. Empirical intravenous antibiotic therapy included piperacillin/tazobactam with antifungal drugs (voriconazole) administered orally. Increasing dyspnea and hypotension were observed. The patient developed multiorgan failure and required catecholamines as well as mechanical treatment. Increasing acidosis was an indication to start continuous renal replacement therapy. The patient died 4 weeks after the initial PCR test because of SARS-CoV-2 complications.

**DISCUSSION**

Since the start of the COVID-19 pandemic, the number of reported organ donors and the number of organ transplants has significantly decreased [11]. The most important reasons might
have been limited access to hospital resources and a limited number of pancreas donors, surge conditions of the pandemic with a shortage of facilities, changes in the availability of transplant centers owing to transformation into infectious centers, as well as deficiency of medical stuff [12,13]. Another important factor might have been SARS-CoV-2 infection among patients on the waiting list. Santos et al [14] reported that 4.6% of kidney-pancreas waiting-list patients were diagnosed with COVID-19. SPK transplantation is safe and feasible in patients convalescing from COVID-19 [15]. In our clinic, there was no case of disqualification owing to COVID-19 infection. Patients infected with the SARS-CoV-2 virus were taken off of the waiting list for approximately 3 months. In 2021, we performed 2 SPK transplantations in patients who recovered from COVID-19 infection, 6 months and 7 months before the transplant, respectively. The early results of organ transplantation in these cases are very good. We also described previously SARS-CoV-2 infection in a kidney recipient [16].

In a Spanish observation, pancreas recipients diagnosed with SARS-CoV-2 infection were just 1% of cases (8 cases out of 778 solid graft recipients registered). The cumulative risk of SARS-CoV-2 infection among pancreas graft recipients was 5.5 out of 1000 for the pancreas, the same as the risk in the

Table 5. Case 18: History of Transplantation for Woman Aged 47 Years

| Donor | Deceased |
|-------|----------|
| Warm ischemia time | 25 min |
| Cold ischemia time | 360 min |
| Induction | Polyclonal antibodies at a dose of 1.5 mg/kg |
| Immunosuppression | Steroids, tacrolimus, mycophenolate mofetil |
| Transplant complications | Early kidney graft loss (vascular complications), HD |
| Surgical site infection | Intra-abdominal infection |

HD, hemodialysis.
Spanish population [17]. In the observation, 2 patients required intensive care unit stays, 4 patients were ventilated mechanically, and 1 patient developed multigorgan failure [17].

Dube et al [18] described 4 cases of pancreas recipients diagnosed with SARS-CoV-2; among them, 1 patient from the observation died and 50% of cases reported diarrhea as a major symptom of the disease. Diarrhea was one of the most frequent complaints in our own observation, including two cases that led to hypovolemia, hospital referral, and need of intravenous fluid administration. The reason for the increased incidence of diarrhea is unclear.

The course of COVID-19 might be serious. Yi reported the use of anakinra in a severe case and respiratory failure [19]. Heron described the successful use of mammalian target of rapamycin inhibitors as an alternative to immunosuppression that could change the course of COVID-19 owing to their antiviral features [20].

In 1 case, we observed late pancreas venous graft thrombosis (PVGT). The occurrence of PVGT varies from 10% to 20% of cases [21,22] and is the most frequent indication for graftectomy [21]. Incidence of PVGT is increased by technical issues such as harvesting method, preservation, cold ischemia time, donor and recipient characteristics, inflammatory factors, or coagulopathy and prophylactic anticoagulant administration [23,24]. In our cohort, the incidence of graft failure due to PVGT in association with COVID-19 was 20%. More observations need to be done to verify if COVID-19 increases the risk of PVGT, but some data suggests that COVID-19 patients are predisposed to PVGT [25,26]. A case of renal allograft late infarction in a 46-year-old COVID-19-positive recipient 13 years after kidney-pancreas transplant was reported [27].

CONCLUSIONS
The incidence of COVID-19 infection among pancreas recipients is similar to that of the general population, but immunosuppression and history of dialysis might increase the risk of death and serious complications. In our study, we did not observe an increased graft loss associated with SARS-CoV-2, but, in the general population, the infection is associated with thrombotic complications. There is a need for a multicenter analysis of solid graft recipients and the creation of guidelines regarding...
referrals for hospitalization, immunosuppression modifications, and anticoagulants.

REFERENCES

[1] Worldometer, <https://www.worldometers.info>; [accessed 30.01.22].

[2] Tygodnik Medyczny, <https://tygodnikmedyczny.pl/nefrolog-osoby-dializowane-choruja-na-covid-19-osiem-razy-czesciej-niz-reszta-populacji>; [accessed 11.08.2021].

[3] BIBA Medical. Renal interventions. <https://renalinterventions.net/girft-report-renal-medicine-webinar-uk-kidney-disease/>; [accessed 29.11.21].

[4] Aslam S, Goldstein DR, Vos R, Gelman AE, Kittleson MM, Wolfe C, et al. COVID-19 vaccination in our transplant recipients: the time is now. J Heart Lung Transplant 2021;40:169–71.

[5] American Society of Transplantation. COVID-19: Vaccine FAQ sheet. <https://www.myast.org/covid-19-vaccine-faq-sheet>; [accessed 28.01.22].

[6] Poltransplant. Poltransplants position in Covid-19, <https://poltransplant.pl/Download/covid/2021_01_15_Stanowisko_Poltransplantu_ws_Covid_19.pdf>; [accessed 15.01.21].

[7] Surowiecka-Pastewka A, Matejak-Górska M, Frączek M, Skłinda K, Wałęcki J, Durlik M. Endovascular interventions in vascular complications after simultaneous pancreas and kidney transplantations: a single-center experience. Ann Transplant 2019;24(2):199–207.

[8] Surowiecka A, Feng S, Matejak-Górska M, Durlik M. Influence of peritoneal or hemodialysis on results of simultaneous pancreas and kidney transplant. Exp Clin Transplant 2020;18:8–12.

[9] Surowiecka-Pastewka A, Matejak-Górska M, Frączek M, Durlik M. Reconstruction of multiple renal arteries during simultaneous pancreas and kidney transplantation: a case report. Transplant Proc 2018;50:2136–9.

[10] Surowiecka A, Frączek M, Mruk B, Matejak-Górska M, Wałęcki J, Durlik M, et al. Normal pancreas graft appearance in magnetic resonance diffusion tensor imaging (DTI). Med Sci Monit 2020;26:e920262.

[11] Poltransplant. Poltransplant Newsletter 2021, <https://www.poltransplant.pl/Download/Biuletyn_2021_www.pdf>; [accessed 30.01.22].

[12] Garcia VD, Pégo-Fernandes PM. Organ transplantation and COVID-19. Sao Paulo Med J 2021;139:301–4.

[13] Woodside KJ, Singh N, Lentine KL, Pavlakis M, Basu A, Cabeza Rivera FH, et al. Approach to pancreas transplant during the COVID-19 pandemic. Clin Transplant 2021;35:e14177.

[14] Santos CAQ, Rhee Y, Hollinger EF, Olaitan OK, Schadde E, Peev V, et al. Comparative incidence and outcomes of COVID-19 in kidney or kidney-pancreas transplant recipients versus kidney or kidney-pancreas waitlisted patients: A single-center study. Clin Transplant 2021;35:e14362.

[15] Singh N, Tandukar S, Zibari G, Naseer MS, Amiri HS, Sama-niego-Picota MD. Successful simultaneous pancreas and kidney transplant in a patient post-COVID-19 infection. Kidney Int 2020;98:1615–6.

[16] Kędzierska-Kapuza K, Zielinńska D, Matejak-Górska M, Durlik M. The course of SARS-CoV-2 in a patient after a recent kidney transplant: a literature review on COVID-19 therapy. Transplant Proc 2021;53:1194–201.

[17] Coll E, Fernández-Ruiz M, Sánchez-Álvarez JE, Martínez-Fernández JR, Crespo M, Gayoso J, et al. COVID-19 in transplant recipients: the Spanish experience. Am J Transplant 2021;21:1825–37.

[18] Dube GK, Husain SA, McCune KR, Sandoval PR, Ratner LE, Cohen DJ. COVID-19 in pancreas transplant recipients. Transpl Infect Dis 2020;22:e13559.

[19] Yi SG, Rogers AW, Saharia A, Aoun M, Faour R, Abdelrahim M, et al. Early experience with COVID-19 and solid organ transplantation at a US high-volume transplant center. Transplantation 2020;104:2208–14.

[20] Heron VC, Bach CT, Holmes NE, Whitlam JB. Complete recovery from COVID-19 of a kidney-pancreas transplant recipient: potential benefit from everolimus? BMJ Case Rep 2021;14:e238413.

[21] Han K, Ko HK, Tsuo J, Shim DJ, Kim Y, Ko Gi-Y, et al. Endovascular management for the treatment of pancreas transplant venous thrombosis: a single-center experience. JVIR 2016;27:882–8.

[22] Reslan OM, Kirsch JM, Kaul H, Campos S, Zaki R, Brady PS, et al. Endovascular stenting of portal vein for graft regraft after a pancreas transplant venous graft thrombosis: a case report. Ann Vasc Surg 2017;42:301.e13-301/e17.

[23] Tobben PJ, Zajko AB, Sumkin JH, Bowen A, Fuhrman CR, Skolnick ML, et al. Pseudoaneurysms complicating organ transplantation: roles of CT, duplex sonography, and angiography. Radiology 1988;169:65–70.

[24] Nagai S, Powelson JA, Taber TE, Goble ML, Mangus RS, Friedell JA. Allograft pancreatectomy: indications and outcomes. Am J Transplant 2015;15:2456–64.

[25] Lliñós JF, Leclere M, Chochois C, et al. High incidence of venous thromboembolic events in anticoagulated severe COVID-19 patients. J Thromb Haemost 2020;18:1743–6.

[26] Cui S, Chen S, Li X, Liu S, Wang F. Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia. J Thromb Haemost 2020;18:1421–4.

[27] Xu JJ, Samaha D, Moudhe S, Massicotte-Azamioch D, Knoll G, Ruzicka M. Renal infarct in a COVID-19-positive kidney-pancreas transplant recipient. Am J Transplant 2020;20:3221–4.